Skip to content

Drug evaluation: Tagatose in the treatment of type 2 diabetes and obesity

by Moore M.C.
Current Opinion in Investigational Drugs ()

Abstract

Spherix Inc (formerly Biospherics) is developing tagatose, an orally active lactose derivative for the potential treatment of obesity and type 2 diabetes. The compound is also under investigation for the potential treatment of anemia, hemophilia and medical problems related to infertility, birth weight and excessive maternal food intake. Phase I and II clinical trials have been completed. (copyright) The Thomson Corporation.

Cite this document (BETA)

Readership Statistics

1 Reader on Mendeley
by Discipline
 
100% Medicine and Dentistry
by Academic Status
 
100% Researcher

Sign up today - FREE

Mendeley saves you time finding and organizing research. Learn more

  • All your research in one place
  • Add and import papers easily
  • Access it anywhere, anytime

Start using Mendeley in seconds!

Sign up & Download

Already have an account? Sign in